Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia

ClinicalTrials.gov ID: NCT00674752

Public ClinicalTrials.gov record NCT00674752. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter, Polysomnographic Study Of Gabapentin 250 mg And 500 mg In Transient Insomnia Induced By A Sleep Phase Advance

Study identification

NCT ID
NCT00674752
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
377 participants

Conditions and interventions

Interventions

  • Gabapentin Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2006
Primary completion
Not listed
Completion
Jul 31, 2006
Last update posted
Feb 1, 2021

2006

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Pfizer Investigational Site Miami Florida 33143
Pfizer Investigational Site Atlanta Georgia 30342
Pfizer Investigational Site Overland Park Kansas 66212
Pfizer Investigational Site Cincinnati Ohio 45227

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00674752, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 1, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00674752 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →